Contrast enhancement, G-CIMP subtype, and homozygous deletion in -mutant astrocytoma.
作者信息
Khan Mehak Majid, Shi Wenyin, Alnahhas Iyad
机构信息
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
出版信息
Neurooncol Adv. 2025 Jun 26;7(1):vdaf136. doi: 10.1093/noajnl/vdaf136. eCollection 2025 Jan-Dec.
Abstract
摘要
相似文献
1
Contrast enhancement, G-CIMP subtype, and homozygous deletion in -mutant astrocytoma.-突变型星形细胞瘤中的对比增强、G-CIMP亚型和纯合缺失。
Neurooncol Adv. 2025 Jun 26;7(1):vdaf136. doi: 10.1093/noajnl/vdaf136. eCollection 2025 Jan-Dec.
2
A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.一项关于异柠檬酸脱氢酶（IDH）突变型4级胶质瘤的多中心临床分析：对预后和临床试验设计的意义
J Neurooncol. 2025 Jan;171(2):373-381. doi: 10.1007/s11060-024-04852-7. Epub 2024 Oct 21.
3
The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma.CDKN2A/B半合子缺失在异柠檬酸脱氢酶（IDH）突变型胶质瘤中的预后影响
Neuro Oncol. 2025 Mar 7;27(3):743-754. doi: 10.1093/neuonc/noae238.
4
A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.一种结合组织学分级与CDKN2A纯合及半合子缺失的新型分级系统，用于预测IDH突变型星形细胞瘤的预后。
J Neuropathol Exp Neurol. 2024 Jan 19;83(2):125-130. doi: 10.1093/jnen/nlad112.
5
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.CDKN2A/B 纯合缺失在异柠檬酸脱氢酶突变星形细胞瘤中的转化意义。
Neuro Oncol. 2023 Jan 5;25(1):28-36. doi: 10.1093/neuonc/noac205.
6
A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.一种新型基于 MRI 的深度学习网络结合注意力机制，用于预测 IDH 突变型星形细胞瘤中 CDKN2A/B 纯合缺失状态。
Eur Radiol. 2024 Jan;34(1):391-399. doi: 10.1007/s00330-023-09944-y. Epub 2023 Aug 8.
7
Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI.基于 MRI 的深度学习放射组学模型在异柠檬酸脱氢酶突变型星形细胞瘤中 CDKN2A/B 纯合缺失状态的术前鉴别
J Magn Reson Imaging. 2024 May;59(5):1655-1664. doi: 10.1002/jmri.28945. Epub 2023 Aug 9.
8
CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.在异柠檬酸脱氢酶（IDH）突变型星形细胞瘤中，CDKN2A突变与纯合缺失具有同等的预后意义。
J Neuropathol Exp Neurol. 2023 Sep 20;82(10):845-852. doi: 10.1093/jnen/nlad063.
9
T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant.T2-FLAIR不匹配征，一种用于IDH突变型非强化星形细胞瘤中CDKN2A完整状态的影像学生物标志物。
Neurosurg Rev. 2024 Aug 9;47(1):412. doi: 10.1007/s10143-024-02632-5.
10
Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.与 IDH 突变型 2 至 4 级星形细胞瘤患者预后相关的分子标志物：一项系统综述。
Eur J Cancer. 2022 Nov;175:214-223. doi: 10.1016/j.ejca.2022.08.016. Epub 2022 Sep 21.
本文引用的文献
1
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.伏立西尼在异柠檬酸脱氢酶突变型胶质瘤治疗中的作用。
Neuro Oncol. 2024 Dec 25. doi: 10.1093/neuonc/noae259.
2
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?IDH 突变型胶质瘤中肿瘤分级、年龄、强化和切除程度的生物学意义：在 IDH 抑制剂时代，它们应如何影响治疗决策？
Neuro Oncol. 2024 Oct 3;26(10):1805-1822. doi: 10.1093/neuonc/noae107.
3
T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.T2-FLAIR 错配信号预测 IDH 突变星形细胞瘤中的 DNA 甲基化亚类和 CDKN2A/B 状态。
Clin Cancer Res. 2024 Aug 15;30(16):3512-3519. doi: 10.1158/1078-0432.CCR-24-0311.
4
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.沃拉西尼布治疗 IDH1 或 IDH2 突变型低级别胶质瘤。
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
5
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.由MGMT-STP27算法确定的MGMT启动子甲基化对异柠檬酸脱氢酶（IDH）突变的间变性星形细胞瘤中替莫唑胺的疗效无预测价值。
Neuro Oncol. 2022 Apr 1;24(4):665-667. doi: 10.1093/neuonc/noac014.
6
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
7
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.胶质母细胞瘤中的 IDH 突变：分子机制与潜在治疗靶点。
Br J Cancer. 2020 May;122(11):1580-1589. doi: 10.1038/s41416-020-0814-x. Epub 2020 Apr 15.
8
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.分子分析揭示弥漫性胶质瘤的生物学离散亚群和进展途径。
Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028.
9
The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository.癌症影像档案库（TCIA）：维护和运营公共信息知识库。
J Digit Imaging. 2013 Dec;26(6):1045-57. doi: 10.1007/s10278-013-9622-7.
10
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.利用 cBioPortal 进行复杂癌症基因组学和临床特征的综合分析
Sci Signal. 2013 Apr 2;6(269):pl1. doi: 10.1126/scisignal.2004088.
Zotero 插件